Retinal disease is a significant public health issue that is now affecting more of us than ever before. The number of people living with two of the leading causes of vision loss - Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) - worldwide is set to grow,5-13 further increasing the pressure on health system capacity.
Projected number of people living with retinal disease5-10
These diseases can have a devastating impact upon our work, our health systems, and those we care about most by closing the window to independence.
People may struggle to:14-18
Those living with vision loss and impairment (and often their loved ones too), must also manage the financial costs of: 14,15
Although anti-VEGF therapies have redefined the care of patients with retinal diseases, new treatments are still required to reduce treatment burden
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.
This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.